Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor α antagonists-Reference-Cited by-同舟云学术

Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor α antagonists

Published:2007-12 Issue:12 Volume:56 Page:4226-4227
ISSN:0004-3591
Container-title:Arthritis & Rheumatism
language:en
Short-container-title:Arthritis Rheum

Author:

Curtis Jeffrey R.,Xi Juan,Patkar Nivedita,Xie Aiyuan,Saag Kenneth G.,Martin Carolyn

Publisher

Wiley

Subject

Pharmacology (medical),Immunology,Rheumatology,Immunology and Allergy

Reference6 articles.

1. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists;Curtis;Arthritis Rheum,2007

2. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy;Wolfe;Arthritis Rheum,2006

3. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register;Dixon;Arthritis Rheum,2006

4. Infections in patients with rheumatoid arthritis treated with biologic agents;Listing;Arthritis Rheum,2005

5. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials;Bongartz;JAMA,2006

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of serious infections, including Mycobacterium tuberculosis, during treatment with biologic disease-modifying anti-rheumatic drugs: does line of therapy matter?;Rheumatology;2023-09-27

2. Risk of severe infections after the introduction of biologic DMARDs in people with newly diagnosed rheumatoid arthritis: a population-based interrupted time-series analysis;Rheumatology;2023-04-04

3. Adherence patterns in naïve and prevalent use of infliximab and its biosimilar;BMC Rheumatology;2022-11-01

4. Development, Optimization, and In Vivo Validation of New Imidazopyridine Chemotypes as Dual TLR7/TLR9 Antagonists through Activity-Directed Sequential Incorporation of Relevant Structural Subunits;Journal of Medicinal Chemistry;2022-08-12

5. Clinical course of patients with rheumatoid arthritis who continue or discontinue biologic therapy after hospitalization for infection: a retrospective observational study;Arthritis Research & Therapy;2022-06-01